Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

Amin A, Benavides LC, Holmes JP, Gates JD, Carmichael MG, Hueman MT, Mittendorf EA, Storrer CE, Jama YH, Craig D, Stojadinovic A, Ponniah S, Peoples GE.

Cancer Immunol Immunother. 2008 Dec;57(12):1817-25. doi: 10.1007/s00262-008-0509-2. Epub 2008 Apr 8.

PMID:
18392824
2.

Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

Peoples GE, Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S, Dehqanzada ZA, Gurney JM, Woll MM, Ryan GB, Storrer CE, Craig D, Ioannides CG, Ponniah S.

Clin Cancer Res. 2008 Feb 1;14(3):797-803. doi: 10.1158/1078-0432.CCR-07-1448.

3.

Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technology.

Dehqanzada ZA, Storrer CE, Hueman MT, Foley RJ, Harris KA, Jama YH, Shriver CD, Ponniah S, Peoples GE.

Oncol Rep. 2007 Mar;17(3):687-94.

PMID:
17273752
4.

Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer.

Mittendorf EA, Storrer CE, Shriver CD, Ponniah S, Peoples GE.

Ann Surg Oncol. 2006 Aug;13(8):1085-98. Epub 2006 Jul 24.

PMID:
16865596
5.

Analysis of naïve and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine.

Hueman MT, Stojadinovic A, Storrer CE, Dehqanzada ZA, Gurney JM, Shriver CD, Ponniah S, Peoples GE.

Cancer Immunol Immunother. 2007 Feb;56(2):135-46. Epub 2006 Jun 17.

PMID:
16783576
6.

Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine.

Hueman MT, Stojadinovic A, Storrer CE, Foley RJ, Gurney JM, Shriver CD, Ponniah S, Peoples GE.

Breast Cancer Res Treat. 2006 Jul;98(1):17-29. Epub 2006 Jun 7.

PMID:
16758122
7.

Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.

Mittendorf EA, Storrer CE, Foley RJ, Harris K, Jama Y, Shriver CD, Ponniah S, Peoples GE.

Cancer. 2006 Jun 1;106(11):2309-17.

8.

Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer.

Mittendorf EA, Gurney JM, Storrer CE, Shriver CD, Ponniah S, Peoples GE.

Surgery. 2006 Mar;139(3):407-18.

PMID:
16546506
9.

Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients.

Dehqanzada ZA, Storrer CE, Hueman MT, Foley RJ, Harris KA, Jama YH, Kao TC, Shriver CD, Ponniah S, Peoples GE.

Clin Cancer Res. 2006 Jan 15;12(2):478-86.

10.

Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients.

Hueman MT, Dehqanzada ZA, Novak TE, Gurney JM, Woll MM, Ryan GB, Storrer CE, Fisher C, McLeod DG, Ioannides CG, Ponniah S, Peoples GE.

Clin Cancer Res. 2005 Oct 15;11(20):7470-9.

11.

Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.

Peoples GE, Gurney JM, Hueman MT, Woll MM, Ryan GB, Storrer CE, Fisher C, Shriver CD, Ioannides CG, Ponniah S.

J Clin Oncol. 2005 Oct 20;23(30):7536-45. Epub 2005 Sep 12.

PMID:
16157940
12.

Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells recognizing HER2/neu vaccine peptides.

Mittendorf EA, Storrer CE, Shriver CD, Ponniah S, Peoples GE.

Breast Cancer Res Treat. 2005 Jul;92(1):85-93.

PMID:
15980996
13.

Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients.

Woll MM, Fisher CM, Ryan GB, Gurney JM, Storrer CE, Ioannides CG, Shriver CD, Moul JW, McLeod DG, Ponniah S, Peoples GE.

J Clin Immunol. 2004 Jul;24(4):449-61.

PMID:
15163902
14.

Spontaneous formation of germinal centers in autoimmune mice.

Luzina IG, Atamas SP, Storrer CE, daSilva LC, Kelsoe G, Papadimitriou JC, Handwerger BS.

J Leukoc Biol. 2001 Oct;70(4):578-84.

PMID:
11590194
15.

Vasculitis in the Palmerston North mouse model of lupus: phenotype and cytokine production profile of infiltrating cells.

Luzina IG, Knitzer RH, Atamas SP, Gause WC, Papadimitriou JC, Sztein MB, Storrer CE, Handwerger BS.

Arthritis Rheum. 1999 Mar;42(3):561-8.

16.

Further characterization of the autoantibody response of Palmerston North mice.

Handwerger BS, Storrer CE, Wasson CS, Movafagh F, Reichlin M.

J Clin Immunol. 1999 Jan;19(1):45-57.

PMID:
10080104

Supplemental Content

Loading ...
Support Center